Reporting on Adverse Clinical Events, 2018

DOI: 10.1177/0069477018805392

Keywords: Atezolizumab (263),Budesonide (265),Clozapine (267),Fluoroquinolones (273),Glimepiride (264),Lapatinib (271),Minocycline (272),Nilotinib (262),Programmed Death-1 Inhibitors (268),Polyethylene Glycol (275),Ranolazine (266),Risperidone (269),Valsartan/Sacubitril (270),Vedolizumab (274)

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text